Home Your basket
• Reconstruction of a trans...
   Price 8.50 €
• Use of inomeric cement: P...
   Price 10.50 €
• Endobronchial lipomas and...
   Price 5.50 €
• Pulsatile tinnitus and ve...
   Price 8.50 €
• Cervical lymph node metas...
   Price 8.50 €
• BAHA in single sided deaf...
   Price 12.50 €
• Augmentation of the abdom...
   Price 10.50 €
• The relevance of Choukrou...
   Price 10.50 €
• Moderate leukocyte infilt...
   Price 10.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• Carotid body paragangliom...
   Price 8.50 €
• Setting up a «Bonebridge»...
   Price 10.50 €
• A survey of current wound...
   Price 5.50 €
• Diagnostic value of vibra...
   Price 8.50 €
• Voice rehabilitation afte...
   Price 10.50 €
• Post-operative complicati...
   Price 10.50 €
• Teeth and sinuses...
   Price 8.50 €
• Laryngeal tuberculosis: A...
   Price 5.50 €
• A rare tumor of the parap...
   Price 5.50 €
• Frontal sinus osteoma com...
   Price 5.50 €
• Objective analysis of pos...
   Price 8.50 €
• Audit of headache followi...
   Price 5.50 €
• The tensegrity concept ap...
   Price 10.50 €
• Role of diffusion weighte...
   Price 10.50 €
• The rehabilitation of the...
   Price 10.50 €
• Long-term results of faci...
   Price 10.50 €
• Microdebrider-assisted pa...
   Price 10.50 €
• Advantages of combined th...
   Price 10.50 €
• Rhinitis and allergy test...
   Price 8.50 €
• Ethmoidal metastasis reve...
   Price 8.50 €
• Laryngeal cryptococcosis ...
   Price 8.50 €
• Blepharoplasty and upper ...
   Price 10.50 €
• Life after total laryngec...
   Price 8.50 €
• Social integration 15 yea...
   Price 14.00 €
• Vocal rehabilitation with...
   Price 10.50 €
• Nasal tumours of the thre...
   Price 10.50 €
• Sinonasal hemangiopericyt...
   Price 5.50 €
• Auditory screening in neo...
   Price 8.50 €
• Supra and infra hyoid mid...
   Price 10.50 €
• The effects of treatments...
   Price 14.00 €
• Synovial sarcoma of the h...
   Price 5.50 €
• Botulinum toxin, descript...
   Price 12.50 €
• Progressive cochleo-vesti...
   Price 5.50 €
• Balance disorders in the ...
   Price 8.50 €
• Nasal glioma, diagnosis i...
   Price 12.00 €
• Voice after supracricoid ...
   Price 10.50 €
• Recurrent mandibular amel...
   Price 12.50 €
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Today’s importance of ult...
   Price 14.00 €
• Interest of MIBI scintigr...
   Price 10.50 €
• Osteointegrated cranio-fa...
   Price 10.50 €
• Sinonasal hemangiopericyt...
   Price 10.50 €
• Protruding ears...
   Price 8.50 €
• Comparative study using A...
   Price 10.50 €
• Prevalence of and risk fa...
   Price 10.50 €
• Otomycosis: Clinical and ...
   Price 5.50 €
• Central auditory processi...
   Price 10.50 €
• Ethmoid-nasal meningioma ...
   Price 10.00 €
• Chyle leak after cervical...
   Price 15.00 €
• Active bone conduction im...
   Price 12.00 €
• Comparison between extern...
   Price 10.50 €
• MIF in Head and Neck canc...
   Price 10.50 €
• How to predict post thyro...
   Price 12.00 €
• Kikuchi-Fujimoto’s diseas...
   Price 5.50 €
• Hearing aid : practical a...
   Price 8.50 €
• Adaptation and validation...
   Price 10.50 €
• A comparative study of br...
   Price 10.50 €
• Aneurysmal bone cyst of t...
   Price 5.50 €
• Subacute tuberculous otit...
   Price 8.50 €
• Advantages of combined th...
   Price 10.50 €
• The European Evaluation o...
   Price 8.50 €
• Association of thyroid he...
   Price 12.50 €
• Assessment of migraine re...
   Price 8.50 €
• Preliminary experimental ...
   Price 10.50 €
• Study of the supra-glotti...
   Price 10.50 €
• Acute infectious complica...
   Price 8.50 €
• Smile "forced" smile vers...
   Price 10.50 €
• The value of the operatin...
   Price 10.50 €
• The value of fine-needle ...
   Price 10.50 €

Total Order 748.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2008 o

OTONEUROLOGY

Disability in patients with Menière’s disease following the use of two different treatment modalities: Betahistine and intratympanic gentamicin


Authors : Enrique-Gonzalez A, Sánchez-Ferrándiz N, Pérez-Fernández N. (Pamplona)

Ref. : Rev Laryngol Otol Rhinol. 2008;129,4:249-254.

Article published in english
Downloadable PDF document english



Summary : Objective: The objective of this study was to assess the level of residual disability and handicap in patients with Menière’s disease (MD) that were free of new vertigo spells 2 years after having been administered treatment with either oral medication or with intratympanic gentamcin. Setting: University hospital. Tertiary medical center. Material and method: 40 patients with MD were included in this study, of which 20 were treated with oral medication (betahistine) and 20 with intratympanic gentamicin; intratympanic gentamicin was for patients considered failures for the oral medication treatment. All of them are free of new vertigo in the 16-24 month period after beginning the treatment. They were matched by age and disease duration. Disability and handicap were assessed with conventional questionnaires at the time of inclusion and 2 years after beginning oral medication or ended the intratympanic gentamicin treatment. According to the treatment two groups were created: oral medication treatment and intratympanic gentamicin treatment. Results: The amount of disability before treatment was higher in patients treated with intratympanic gentamicin than in those under oral medication; However, after treatment when no more vertigo spells takes place, this disability is significantly reduced and becomes similar for both groups of patients. In patients treated with oral medication the items reflecting the intensity of vertigo spell, the impact of vertigo in daily activities, the perception of quality of life and level of somatization do not show a significant reduction. Conclusion: The number or frequency of vertigo spells are very relevant for the process of disability and handicap of patients with MD when that is low or when oral medication is sufficient to eliminate vertigo spells. However when that number is high and the only possibility to arrest those vertigo spells is the use of intratympanic gentamicin, fear of vertigo must be considered as an associated problem for the patient.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE